ATRS Antares Pharma Inc

Price (delayed)

$3.81

Market cap

$643.12M

P/E Ratio

9.77

Dividend/share

N/A

EPS

$0.39

Enterprise value

$629.73M

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has ...

Highlights
Antares Pharma's equity has surged by 130% YoY and by 4.6% QoQ
ATRS's P/E is 50% below its last 4 quarters average of 19.8
ATRS's quick ratio is down by 36% year-on-year

Key stats

What are the main financial stats of ATRS
Market
Shares outstanding
168.8M
Market cap
$643.12M
Enterprise value
$629.73M
Valuations
Price to earnings (P/E)
9.77
Price to book (P/B)
4.87
Price to sales (P/S)
3.76
EV/EBIT
26.34
EV/EBITDA
23.14
EV/Sales
3.68
Earnings
Revenue
$171.2M
EBIT
$23.9M
EBITDA
$27.21M
Free cash flow
$11.12M
Per share
EPS
$0.39
Free cash flow per share
$0.07
Book value per share
$0.78
Revenue per share
$1.01
TBVPS
$1.21
Balance sheet
Total assets
$212.62M
Total liabilities
$80.59M
Debt
$31.74M
Equity
$132.03M
Working capital
$55.99M
Liquidity
Debt to equity
0.24
Current ratio
1.78
Quick ratio
1.38
Net debt/EBITDA
-0.49
Margins
EBITDA margin
15.9%
Gross margin
70.5%
Net margin
37.7%
Operating margin
24.5%
Efficiency
Return on assets
32.3%
Return on equity
58.4%
Return on invested capital
19.7%
Return on capital employed
17%
Return on sales
14%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATRS stock price

How has the Antares Pharma stock price performed over time
Intraday
-0.52%
1 week
1.87%
1 month
-3.79%
1 year
43.77%
YTD
-4.51%
QTD
-12.61%

Financial performance

How have Antares Pharma's revenue and profit performed over time
Revenue
$171.2M
Gross profit
$120.63M
Operating income
$42.02M
Net income
$64.6M
Gross margin
70.5%
Net margin
37.7%
The operating income has soared by 162% YoY and by 20% from the previous quarter
The company's operating margin has surged by 111% YoY and by 11% QoQ
ATRS's gross profit is up by 34% year-on-year and by 11% since the previous quarter
ATRS's revenue is up by 24% YoY and by 8% QoQ

Growth

What is Antares Pharma's growth rate over time

Valuation

What is Antares Pharma stock price valuation
P/E
9.77
P/B
4.87
P/S
3.76
EV/EBIT
26.34
EV/EBITDA
23.14
EV/Sales
3.68
ATRS's P/E is 50% below its last 4 quarters average of 19.8
Antares Pharma's EPS has increased by 5% QoQ
Antares Pharma's equity has surged by 130% YoY and by 4.6% QoQ
The price to book (P/B) is 53% lower than the 5-year quarterly average of 10.5 and 17% lower than the last 4 quarters average of 5.9
The P/S is 37% below the 5-year quarterly average of 6.0 and 8% below the last 4 quarters average of 4.1
ATRS's revenue is up by 24% YoY and by 8% QoQ

Efficiency

How efficient is Antares Pharma business performance
The ROIC has soared by 119% YoY and by 15% from the previous quarter
Antares Pharma's return on sales has surged by 97% YoY and by 9% QoQ
Antares Pharma's return on equity has decreased by 14% QoQ
The company's return on assets fell by 6% QoQ

Dividends

What is ATRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATRS.

Financial health

How did Antares Pharma financials performed over time
The total assets is 164% greater than the total liabilities
The total assets is up by 49% year-on-year but it has declined by 2.7% since the previous quarter
The current ratio has contracted by 39% YoY and by 3.8% from the previous quarter
Antares Pharma's debt is 76% less than its equity
Antares Pharma's equity has surged by 130% YoY and by 4.6% QoQ
The debt to equity has dropped by 71% year-on-year and by 35% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.